Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04593784 · ClinicalTrials.gov registry record · Phase 2
Study of Ciraparantag for Reversal of Anticoagulation Induced by Edoxaban, Apixaban or Rivaroxaban in Healthy Adults
A Phase 2 study, sponsored by AMAG Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT04593784 is a Phase 2 study that was terminated before completion, run by AMAG Pharmaceuticals. The registered enrollment target is 41 participants.
The verdict
NCT04593784, a Phase 2 study, was terminated before completion, sponsored by AMAG Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ciraparantag for reversal of anticoagulation induced by different anticoagulant drugs in generally healthy adults as measured primarily by an automated coagulometer device.
Interventions
- DRUG Placebo
- DRUG Ciraparantag
- DEVICE Point-of-Care Coagulometer (investigational device)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2021-10-13 |
| Est. Completion | 2023-08-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04593784
The ClinicalTrials.gov registry entry for NCT04593784 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AMAG Pharmaceuticals, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04593784 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04593784 about?
NCT04593784 is a clinical study titled "Study of Ciraparantag for Reversal of Anticoagulation Induced by Edoxaban, Apixaban or Rivaroxaban in Healthy Adults". A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ciraparantag for reversal of anticoagulation induced by different anticoagulant drugs in generally healthy adults as measured primarily by an automated coagulometer device.
What is the current status of trial NCT04593784?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2021-10-13. Estimated completion is 2023-08-26.
What interventions are being tested in trial NCT04593784?
The interventions under investigation include: Placebo (DRUG), Ciraparantag (DRUG), Point-of-Care Coagulometer (investigational device) (DEVICE).
Who is sponsoring clinical trial NCT04593784?
This trial is sponsored by AMAG Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.